Most Read Articles
Dr. Bob T. Li, 08 Apr 2021
Sotorasib, a first-in-class KRASG12C inhibitor, demonstrated rapid, deep and durable responses with a 6.8-month median progression-free survival (PFS) in patients with KRASG12C-mutated advanced non-small-cell lung cancer (NSCLC) in the phase II CodeBreaK 100 trial. During the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC 2020) held in Singapore in January 2021, Dr Bob T. Li of the Memorial Sloan Kettering Cancer Center in New York, New York, US, presented the encouraging results from the trial.
Tristan Manalac, 3 days ago
The beneficial effects of metabolic bariatric surgery are long-lasting, with improvements in renal function and reductions in albuminuria still apparent 1 year after the procedure, according to a Singapore study presented at the recently concluded ENDO 2021 virtual conference by the Endocrine Society.
Prof. Yun-Kwok Wing, 09 Apr 2021
Insomnia is a highly prevalent disorder associated with substantial functional impairment and social problems globally, yet an efficacious long-term treatment with minimal treatment-emergent adverse events is still lacking. In an interview with MIMS Doctor, Professor Yun-Kwok Wing of the Department of Psychiatry, Chinese University of Hong Kong, discusses the current situation with insomnia in Hong Kong, the available treatment options and their limitations, and ways to bridge existing management gaps.
31 Mar 2021
Romosozumab solution for injection (pre-filled syringe) 105 mg/1.17 mL

Product Highlight - Evenity

31 Mar 2021
Build bone first for your patients at very high fracture risk

• Recommended as the 1st line therapy for patients with very high risk of fractures1
• Significant BMD improvements vs teriparatide in 1 year of therapy2
• Reduced hip, vertebral, and non-vertebral fractures vs alendronate*3
• Convenient monthly subcutaneous administration4

*In the ARCH study, patients receiving 1 year or romosozumab followed by 2 years of alendronate significantly reduced hip, vertebral, and non-vertebral fractures vs patients receiving 3 years of alendronate alone.


References:
1. Camacho PM, Petak SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update. Endocr Pract. 2020; 26(5): 564-570.
2. Langdahl BL, Libanati C, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017; 390(10102): 1585-1594.
3. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017; 377(15): 1417-1427.
4. Evenity HK prescribing information. March 2020.


Related MIMS Drugs

Editor's Recommendations
Most Read Articles
Dr. Bob T. Li, 08 Apr 2021
Sotorasib, a first-in-class KRASG12C inhibitor, demonstrated rapid, deep and durable responses with a 6.8-month median progression-free survival (PFS) in patients with KRASG12C-mutated advanced non-small-cell lung cancer (NSCLC) in the phase II CodeBreaK 100 trial. During the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC 2020) held in Singapore in January 2021, Dr Bob T. Li of the Memorial Sloan Kettering Cancer Center in New York, New York, US, presented the encouraging results from the trial.
Tristan Manalac, 3 days ago
The beneficial effects of metabolic bariatric surgery are long-lasting, with improvements in renal function and reductions in albuminuria still apparent 1 year after the procedure, according to a Singapore study presented at the recently concluded ENDO 2021 virtual conference by the Endocrine Society.
Prof. Yun-Kwok Wing, 09 Apr 2021
Insomnia is a highly prevalent disorder associated with substantial functional impairment and social problems globally, yet an efficacious long-term treatment with minimal treatment-emergent adverse events is still lacking. In an interview with MIMS Doctor, Professor Yun-Kwok Wing of the Department of Psychiatry, Chinese University of Hong Kong, discusses the current situation with insomnia in Hong Kong, the available treatment options and their limitations, and ways to bridge existing management gaps.
31 Mar 2021
Romosozumab solution for injection (pre-filled syringe) 105 mg/1.17 mL